Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
M-VIVA
NCT07249216Recruiting
- Sponsor
- Singapore National Eye Centre
- Start
- Jul 2025
- Primary completion
- Jun 2029
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Open-label trial of faricimab in neovascular age-related macular degeneration (NVAMD) (2 arms), sponsored by Singapore National Eye Centre. Primary endpoint: Difference in vitreous biomarker concentrations between responders and non-responders at 12 weeks. Started Jul 2025; status: recruiting.
02
Drugs
faricimab
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT07249216.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07249216.